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Translating basic research findings into therapeutic settings presents many scientific, logistic, and financial
challenges for academic researchers. Here, I highlight some key insights for navigating such challenges
based on recent clinical trials initiated by basic research from my lab.Introduction
A lot of people are talking about transla-
tional research. It can be defined in
many ways, but a simple rendition would
be the discovery of a new therapeutic in
your own lab and the subsequent clinical
trial to test its activity in humans. This
event is likely to happen only a few times
in a career as a researcher. I trained as a
hematologist/oncologist and intrinsically
want to see translation from the bench
to the bedside. As a physician scientist,
my career has focused on the develop-
mental biology of hematopoiesis, using
the zebrafish as a model system. As the
zebrafish model developed into an excel-
lent chemical genetics system,my labora-
tory began attempting to discover new
therapies and translating the findings to
curing patients. We brought two therapies
from the tank to the bedside, and here, I
will highlight lessons that are critical for
success in translational research based
on my personal experience.
Our Story
My experience with translational research
using the zebrafish involves a project in
which we were trying to improve the
safety and efficacy of blood stem cell
transplantation by discovering drugs that
could increase their number or their po-
tency. In 2007, we undertook a chemical
screen in the zebrafish model in which
a library of small molecules of 2,500
chemicals of known action were screened
for their ability to induce expression of the
hematopoietic stem cell genes runx1 and
c-myb in the developing zebrafish aorta
(North et al., 2007). This screen identi-
fied 35 chemicals capable of inducing
an increased hematopoietic expression
pattern in the aorta, suggesting the pro-146 Cell Stem Cell 14, February 6, 2014 ª201duction of more stem cells. One of
those chemicals was a strong inducer
called 16,16-dimethyl prostaglandin E2
(dmPGE2). This chemical represented
the first small molecule discovered that
can amplify a stem cell population from
an organ. In an effort to see if this could
be therapeutically useful, we undertook
competitive repopulation experiments in
the mouse. dmPGE2 led to a 4-fold in-
crease in the number of stem cells that
engrafted, suggesting that the addition
of prostaglandin could lead to enhanced
engraftment. This work was confirmed
by the Pelus laboratory (Hoggatt et al.,
2009) and further suggested that treat-
ment of dmPGE2 ex vivo could become
a therapy. The process described here
may therefore be applicable to both cell
therapy applications and more traditional
screening efforts.
We next undertook preclinical modeling
using cord blood. To test the efficacy of
dmPGE2 on cord blood units, with the
idea of developing a new therapy to
enhance engraftment, single cord blood
samples were split in half; half was
treated with prostaglandin, while the
other half was left untreated (Goessling
et al., 2011). These were transplanted
into immunodeficient irradiated mice.
The study showed that there was more
human blood in the peripheral blood
of the mice, and they exhibited higher
chimerism in their blood and bonemarrow
3 months later. This was the preclinical
data that allowed us to go to the FDA.
To develop an FDA application, there
were many meetings with the Center for
Human Cell Therapy at the Harvard
Medical School. This group helped us
develop standard operating procedures
for the treatment of the cord blood units4 Elsevier Inc.with dmPGE2. dmPGE2 was given to
patients in the early 1980s for the treat-
ment of stomach ulcers. These studies
demonstrated safety of the drug and
allowed our team to predict that toxicity
in the cord blood trial would be unlikely.
An IND submission occurred in May,
2008 with an FDA response in June of
that year. The FDA, interestingly, did not
open the previous files on dmPGE2 and
relied on the published literature and our
preclinical data. We provided toxicity
data in mice. We generated a clinical
protocol that required vetting through
a Scientific Review Committee at the
hospitals at which the trial was to be
done, the Dana-Farber Cancer Institute,
and Massachusetts General Hospital, as
well as IRB approval. The contents of
the IND application itself, when stacked
and placed on the ground, totaled about
1 foot tall. The FDAprocesswas amended
and approved in 2009. Any alterations in
the manipulation of the cells or changes
to the protocol would have to be reviewed
by the FDA.
As we were ready to proceed with the
clinical trial, we dealt with issues of
manufacturing. We custom ordered a lot
of dmPGE2 that was sufficient for the
entire clinical trial. The academic discov-
ery path to the bedside was efficient, but
as translational costs and standard pro-
cedures became issues, it became clear
that having a company involved would
be an advantage. I had filed the patent
for the use of dmPGE2 for transplantation
and was approached to start a company
based on the technology. FATE Thera-
peutics was formed.
Founding a company is an interesting
process. I was approached by Randy
Moon, a long-term colleague who works
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Phil Beachy were interested in forming
a company to work on stem cells and
were approached by several venture
capital companies, Polaris, ARCH, and
Venrock. These venture groups felt that
this new stem cell company would benefit
from including physician-scientists as
founders. David Scadden also joined the
consortium. Lastly, Rudy Jaenisch had
interesting technology on iPSCs and
was included. FATE Therapeutics had
six initial founders and the venture
firms were able to raise millions of dollars.
The process of forming a startup is
very efficient. Early decisions include
defining the leadership of the company,
particularly choosing a CEO and their
staff. Eventually certain projects were
chosen and dmPGE2 was one of the
lead programs.
We validated our standard operating
procedures by independent use of several
cord bloods, and the first patient was
treated in May 2009. We were able to
obtain NIH funding for the clinical trial,
but a number of presentations and meet-
ings were required to secure this funding.
I was able to transfer the physician IND to
FATE Therapeutics, and they participated
in the clinical trial.
The company was instrumental in
bringing the product to the clinic and
deciphering key differences between the
preclinical and clinical processes. An
initial set of patients was treated with
dmPGE2 that was maintained at a spe-
cific temperature based on our Nature
paper that employed mouse stem cells,
but the temperature was too cold for acti-
vation of cyclic AMP in the human cells.
This discrepancy represented a funda-
mental difference between the preclinical
work in our laboratory and the clinical
work done in the standard operating pro-
cedures in which temperature was greatly
monitored. The company recognized that
the chemical was not active, went back
to the lab to find the optimal conditions,
and then came forward with a change in
the processing protocol. This example
demonstrates how a company can have
a great impact on the product by re-
searching difficulties early on and evalu-
ating the process later.
The clinical trial, which was recently
published, involved 12 new patients who
had leukemia (Cutler et al., 2013). They
lacked matched adult marrow but hadumbilical cord units that were matched.
The patients were between 18 and 65
years of age. In this Phase I trial, the pa-
tients undertook a competitive repopula-
tion in which one of the cord blood units
was treated with dmPGE2 for 120 min.
The trial results demonstrated that in 10
out of the 12 patients, the treated cord
blood preferentially engrafted and the
neutrophils and platelets from the treated
cord blood grafted roughly 4.5 days
earlier than the untreated graft. This small
number of patients demonstrated the
safety of the product and also allowed
the company involved, FATE Therapeu-
tics, for which I am a stockholder, to
move to a Phase II clinical trial. The
translational application of zebrafish was
a significant breakthrough in which a
chemical moved from an embryonic
phenotype in zebrafish through work in
mice to human cord blood samples into
immunodeficient mice. The timeline was
a 36 month period of time from tank to
bedside.
A significant number of people were
involved to get the chemical to become
a product. This included the Principal
Clinical Investigator, Corey Cutler, who
was involved in protocol design and
taking care of the patients. There were
coinvestigators who are oncologists who
donated their time and helped with the
development of the scientific protocol. In
addition, two postdoctoral fellows from
my own laboratory, Trista North, Ph.D.,
and Wolfram Goessling, M.D.-Ph.D.,
were in every meeting weekly for over a
year and a half. The directors of the
CHCT, Les Silberstein and Jerry Ritz,
also participated in these meetings, and
there was great help from their secretarial
staff. At the Dana-Farber Cancer Insti-
tute, the Cell Manipulation Facility was
involved, including a significant number
of statisticians. At Boston Children’s
Hospital it was important for the General
Council and the VP of Research to help
with some of the regulatory events. We
had great help during the IND application
from Regulatory Affairs at the hospital.
There were many discussions from the
Intellectual Property Office at Boston
Children’s Hospital, and ultimately, when
the clinical trial was accomplished, a
company was formed, FATE Therapeu-
tics, that included the medical director
as well as senior investigators in the
company who participated in research.Cell Stem Cell 14Some General Tips
Getting Through the Thought
Process of Moving a Drug to the
Clinic
As one is beginning their scientific pur-
suits as a researcher, it is important to
have the clinic in mind. In every NIH grant,
there is a justification on how the work
will translate into issues of health. My sug-
gestion is to look at those sentences and
evaluate if the work in your lab could
directly help patients. It is vital to involve
M.D.s in discussions to think about trans-
lation. It is wonderful to have a mentor
who is an M.D. with a laboratory, who
can think through how the current tech-
nology could be applied in a clinical
setting. Departments may benefit from
the development of a mentoring system.
At Harvard, we have recently started
educational sessions for translation to
the members of academic departments,
sharing success stories.
Evaluate the Clinical Scenario
An important discovery in the laboratory
may have many applications; however,
it is very important to pick the best appli-
cation to show activity of the agent or
device in humans. There should be a
consultation with disease experts. One
method is to organize a lecture at a
hospital or medical school to the relevant
clinical audience. Picking the right dis-
ease to test a drug is critical, and you
want to get independent feedback on
the best clinical path forward.
Preclinical Testing
The experiments should establish the
proof of principle. In our case, the preclin-
ical testing should support transplan-
tation efficacy in the preclinical model.
Advisory groups can be involved in clin-
ical translation to facilitate these projects.
We had monthly meetings with the Center
for HumanCell Therapy and this was quite
important to success. Funding is required
to do the preclinical testing. There are
many institutions that want to facilitate
translational research and some funding
might be available.
Find Interactive Conversations
Find a mentor. This is absolutely critical
to move to a clinical IND. The mentor
should be someone who has done trans-
lational work before and has gone to
the point of filing an IND with the FDA.
Regulatory help from an institution or
hospital will be needed. There are many
forms to complete and there is a need, February 6, 2014 ª2014 Elsevier Inc. 147
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Technology Transfer Office, as they are
critical to investigate any intellectual
property that may be involved in this pro-
cess, and involve the legal team, because
there will be regulatory issues and
conflicts of interest based on your own
institutional policies. Having adminis-
trative help, such as secretarial work, is
also very important. Probably one of the
most rewarding approaches I had was
to involve the scientists in my own labora-
tory who made the original discovery with
the clinical translation. This facilitates the
work and helps develop the preclinical
work necessary at the FDA.
Protocol
It is very helpful to have the medical team
involved very early on. Developing a pro-
tocol for dmPGE2-treated cells required
a significant number of conversations.
There were about six independent meet-
ings on defining the best approach to
use for the chemical. We involved statisti-
cians to determine the optimal number of
patients that would be treated. Stopping
rules needed to be established if toxicity
occurred, and there would be an evalua-
tion whether or not to proceed.
Continue the Lab Work
There are a number of studies that are
needed for the preclinical work. Once
an IND application has been filed, it is
important to continue that work. There is
plenty of time between submitting the
IND application and when the actual clin-
ical protocol is set. Thework that we did in148 Cell Stem Cell 14, February 6, 2014 ª201the last year before the IND application
was finally approved was critical to the
success of the program. Establish statis-
tics within your own experiments and
collect all samples of tissue that have
been treated for drugs or cells, since
these count as toxicology reports for the
FDA. We did many studies in the mice to
establish the safety of dmPGE2, and the
toxicologic reports were used for the
FDA application.
A Second Shot at Translation
My laboratory has recently put a second
chemical from a zebrafish into a patient.
This involved the treatment of melanoma,
which is a devastating disease, and 50%
of the patients have an activating BRAF
mutation. There is a BRAF inhibitor on
the market called vemurafenib that leads
to a substantial response, but unfortu-
nately, at 6 months the patients relapse.
We undertook a chemical screen to look
for small molecules that block neural
crest development. In the process, we
found that an inhibitor of dihydrooratate
dehydrogenase (DHODH) that affects
pyrimidine biosynthesis led to a block in
transcription elongation, and this affected
the expression of neural crest genes as
well as melanoma formation. We under-
took xenograft studies of human mela-
noma into nude mice, and we treated
the mice using the DHODH inhibitor leflu-
nomide, a drug that is in clinical practice
for arthritis. This led to a substantial
response in tumor growth. A combination
of leflunomide and a BRAF inhibitor led to4 Elsevier Inc.a substantial decrease in tumor volume.
We are currently undertaking a clinical
trial at Massachusetts General Hospital
and the Dana Farber Cancer Institute
using the combination with an end point
to increase the progression-free survival
from 7 months to 10.5 months. We hope
to treat 43 patients and to date, 3 patients
have been treated. These two examples
of bringing chemicals from an animal
model into the clinic have been greatly
instructive to understand the process of
translational research.ACKNOWLEDGMENTS
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